<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066677</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000316454</org_study_id>
    <secondary_id>P30CA006927</secondary_id>
    <secondary_id>FCCC-03003</secondary_id>
    <nct_id>NCT00066677</nct_id>
  </id_info>
  <brief_title>Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer</brief_title>
  <official_title>Phase II and Coagulation Study of rhuMAb-VEGF With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different&#xD;
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and&#xD;
      help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy, such&#xD;
      as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing&#xD;
      or die. Combining bevacizumab with docetaxel may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying bevacizumab and docetaxel to see how well&#xD;
      they work compared to bevacizumab alone in treating patients with metastatic pancreatic&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the progression-free survival of patients with previously treated metastatic&#xD;
           pancreatic adenocarcinoma treated with bevacizumab with or without docetaxel.&#xD;
&#xD;
        -  Determine the objective response rate and overall survival of patients treated with&#xD;
           these regimens.&#xD;
&#xD;
        -  Determine the incidence of thromboembolic events in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label study. Patients are randomized to 1 of 2 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and docetaxel&#xD;
           IV over 1 hour on days 1, 8, and 15.&#xD;
&#xD;
        -  Arm II: Patients receive bevacizumab as in arm I. In both arms, courses repeat every 28&#xD;
           days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 46 patients (23 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped accordining to early stopping rule for futility&#xD;
  </why_stopped>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of registration until the date of death, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Thromboembolic Events</measure>
    <time_frame>93 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>rhuMAB-VEGF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bevacizumab 10 mg/kg by intravenous infusion over 30-90 minutes once every 2 weeks until disease progression, unacceptable toxicity or patient preference.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhuMAB-VEGF and Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhuMAB-VEGF,bevacizumab: 10 mg/kg by intravenous infusion over 30-90 minutes once every 2 weeks docetaxel, Taxotere: 35 mg/m2 given intravenously over 1 hour on days 1, 8, and 15 of each 28 day cycle. Treatment continued until evidence of disease progression, unacceptable toxicity, or patient preference.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhuMAB-VEGF</intervention_name>
    <arm_group_label>rhuMAB-VEGF</arm_group_label>
    <arm_group_label>rhuMAB-VEGF and Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>rhuMAB-VEGF and Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the pancreas&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Unidimensionally measurable disease outside of the pancreas&#xD;
&#xD;
               -  At least 1 lesion at least 20 mm by conventional techniques OR at least 10 mm by&#xD;
                  spiral CT scan&#xD;
&#xD;
          -  Must have received 1, and only 1, prior gemcitabine-containing regimen for metastatic&#xD;
             disease unless disease has recurred within 6 months after treatment with neoadjuvant&#xD;
             or adjuvant gemcitabine-containing therapy&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL (transfusion allowed)&#xD;
&#xD;
          -  No bleeding diathesis or coagulopathy&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 1.5 times ULN&#xD;
&#xD;
          -  INR no greater than ULN&#xD;
&#xD;
          -  PTT no greater than ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  No clinically significant renal impairment&#xD;
&#xD;
          -  Urine protein:creatinine ratio â‰¥ 1.0&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No prior myocardial infarction&#xD;
&#xD;
          -  No prior stroke&#xD;
&#xD;
          -  No clinically significant cardiovascular disease&#xD;
&#xD;
          -  No uncontrolled hypertension (i.e., blood pressure greater than 160/110 mm Hg on&#xD;
             medication)&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
          -  No serious cardiac dysrhythmia requiring medication&#xD;
&#xD;
          -  No peripheral vascular disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history or evidence of CNS disease (e.g, primary brain tumor or seizures not&#xD;
             controlled with standard medical therapy)&#xD;
&#xD;
          -  No other medical condition that would preclude study participation&#xD;
&#xD;
          -  No psychiatric condition that would preclude study participation&#xD;
&#xD;
          -  No other prior or concurrent malignancy that would preclude study participation&#xD;
&#xD;
          -  No significant traumatic injury within the past 28 days&#xD;
&#xD;
          -  No serious, nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent prophylactic granulocyte or platelet growth factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 7 days since prior fine needle aspirations or core biopsies&#xD;
&#xD;
          -  More than 28 days since prior surgery (except closed biopsy or access port placement)&#xD;
&#xD;
          -  More than 28 days since prior open biopsy&#xD;
&#xD;
          -  No concurrent surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior experimental drug study participation&#xD;
&#xD;
          -  More than 4 weeks since prior investigational drugs&#xD;
&#xD;
          -  No other concurrent experimental drug study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J. Cohen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 2011 Feb;34(1):70-5. doi: 10.1097/COC.0b013e3181d2734a.</citation>
    <PMID>20458210</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <results_first_submitted>August 16, 2013</results_first_submitted>
  <results_first_submitted_qc>February 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2021</results_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was conducted at Fox Chase Cancer Center between October 2004 and December 20006.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>rhuMAB-VEGF</title>
          <description>rhuMAB-VEGF :</description>
        </group>
        <group group_id="P2">
          <title>rhuMAB-VEGF and Docetaxel</title>
          <description>rhuMAB-VEGF :&#xD;
docetaxel :</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>rhuMAB-VEGF</title>
          <description>rhuMAB-VEGF :</description>
        </group>
        <group group_id="B2">
          <title>rhuMAB-VEGF and Docetaxel</title>
          <description>rhuMAB-VEGF :&#xD;
docetaxel :</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <time_frame>4 months</time_frame>
        <population>The study was stopped according to the early stopping rule for futility. All patients who entered the study have died.</population>
        <group_list>
          <group group_id="O1">
            <title>rhuMAB-VEGF</title>
            <description>rhuMAB-VEGF :</description>
          </group>
          <group group_id="O2">
            <title>rhuMAB-VEGF and Docetaxel</title>
            <description>rhuMAB-VEGF :&#xD;
docetaxel :</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <population>The study was stopped according to the early stopping rule for futility. All patients who entered the study have died.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="28" upper_limit="120"/>
                    <measurement group_id="O2" value="48" lower_limit="28" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate</title>
        <time_frame>56 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rhuMAB-VEGF</title>
            <description>rhuMAB-VEGF :</description>
          </group>
          <group group_id="O2">
            <title>rhuMAB-VEGF and Docetaxel</title>
            <description>rhuMAB-VEGF :&#xD;
docetaxel :</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>From date of registration until the date of death, assessed up to 5 years</time_frame>
        <population>The study was stopped according to the early stopping rule for futility. None of the patients survived.</population>
        <group_list>
          <group group_id="O1">
            <title>rhuMAB-VEGF</title>
            <description>rhuMAB-VEGF :</description>
          </group>
          <group group_id="O2">
            <title>rhuMAB-VEGF and Docetaxel</title>
            <description>rhuMAB-VEGF :&#xD;
docetaxel :</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>The study was stopped according to the early stopping rule for futility. None of the patients survived.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165" lower_limit="28" upper_limit="480"/>
                    <measurement group_id="O2" value="125" lower_limit="28" upper_limit="480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Thromboembolic Events</title>
        <time_frame>93 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rhuMAB-VEGF</title>
            <description>rhuMAB-VEGF :</description>
          </group>
          <group group_id="O2">
            <title>rhuMAB-VEGF and Docetaxel</title>
            <description>rhuMAB-VEGF :&#xD;
docetaxel :</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Thromboembolic Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>rhuMAB-VEGF</title>
          <description>rhuMAB-VEGF :</description>
        </group>
        <group group_id="E2">
          <title>rhuMAB-VEGF and Docetaxel</title>
          <description>rhuMAB-VEGF :&#xD;
docetaxel :</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DVT/pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nail Changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea and vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Parasthesias</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Watery eyes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was stopped according to the early stopping rule for futility.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Steven J. Cohen</name_or_title>
      <organization>Fox Chase Cancer Center</organization>
      <phone>215-728-2450</phone>
      <email>s_cohen@fccc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

